Remove 2025 Remove Chemotherapy Remove HIV Treatment and Prevention Agents
article thumbnail

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. SHOW MORE This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

3 Although meloxicam injection delivers a non-opioid alternative for pain control, it is not recommended as a first-line agent when rapid onset of analgesia is needed due to its delayed onset. June 10, 2025. Accessed June 10, 2025. 2 REFERENCES 1. PR Newswire. Meloxicam: Selective COX-2 inhibition in clinical practice.

FDA 73